July 27, 2017
A New York federal judge on Wednesday granted Bernstein Litowitz Berger & Grossman LLP's request for $2.7 million in attorneys' fees from BioScrip Inc. after getting the specialty pharmacy to pay shareholders $10.9 million for allegedly lying about fraud tied to Novartis AG's iron-reducing drug Exjade.
February 12, 2016
A New York federal judge has preliminarily signed off on a $10.9 million agreement between BioScrip Inc. and a class of shareholders to settle claims that stock prices fell because the company failed to disclose Anti-Kickback Statute and False Claims Act violations tied to Novartis' iron-reducing drug Exjade.
June 08, 2015
A New York federal judge on Friday found that the U.S. Supreme Court's recent Omnicare ruling doesn't shut down a claim that BioScrip Inc. says was wrongly left over in a securities class action alleging it made misleading statements about its compliance with the False Claims Act and covered up an investigation into a large kickback scheme.
March 27, 2015
The lead plaintiff in a proposed securities class action on Friday blasted BioScrip Inc. for defending itself under the shield of the U.S. Supreme Court's recent Omnicare Inc. ruling, saying its letter to the New York federal judge "badly misstated" the court's actual holding.
October 02, 2013
BioScrip Inc. was hit with a proposed class action Monday alleging shareholders suffered losses when the company's stock price declined following the announcement of a law enforcement investigation into its distribution of Novartis Pharmaceuticals Corp.'s iron reduction drug Exjade.